The University of Adelaide, Population Research and Outcome Studies, Discipline of Medicine, 122 Frome Street, Adelaide, South Australia, 5000, Australia.
Bone Joint Res. 2012 May 1;1(5):93-8. doi: 10.1302/2046-3758.15.2000039. Print 2012 May.
To assess the sensitivity and specificity of self-reported osteoporosis compared with dual energy X-ray absorptiometry (DXA) defined osteoporosis, and to describe medication use among participants with the condition.
Data were obtained from a population-based longitudinal study and assessed for the prevalence of osteoporosis, falls, fractures and medication use. DXA scans were also undertaken.
Overall 3.8% (95% confidence interval (CI) 3.2 to 4.5) of respondents and 8.8% (95% CI 7.5 to 10.3) of those aged ≥ 50 years reported that they had been diagnosed with osteoporosis by a doctor. The sensitivity (those self-reporting osteoporosis and having low bone mineral density (BMD) on DXA) was low (22.7%), although the specificity was high (94.4%). Only 16.1% of those aged ≥ 50 years and with DXA-defined osteoporosis were taking bisphosphonates.
The sensitivity of self-reporting to identify osteoporosis is low. Anti-osteoporotic medications are an important part of osteoporosis treatment but opportunities to use appropriate medications were missed and inappropriate medications were used.
评估与双能 X 射线吸收法（DXA）定义的骨质疏松症相比，自我报告的骨质疏松症的敏感性和特异性，并描述该疾病患者的药物使用情况。
数据来自基于人群的纵向研究，评估了骨质疏松症、跌倒、骨折和药物使用的患病率。还进行了 DXA 扫描。
总体而言，3.8%（95%置信区间（CI）3.2 至 4.5）的受访者和 8.8%（95% CI 7.5 至 10.3）的年龄≥50 岁的受访者报告说他们曾被医生诊断患有骨质疏松症。自我报告患有骨质疏松症且 DXA 检查显示骨密度低（BMD）的患者的敏感性（22.7%）较低，尽管特异性（94.4%）较高。仅 16.1%的年龄≥50 岁且 DXA 定义为骨质疏松症的患者服用双膦酸盐。
自我报告骨质疏松症的敏感性较低。抗骨质疏松症药物是骨质疏松症治疗的重要组成部分，但错过了使用适当药物的机会，并使用了不适当的药物。
